Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder.
Where this comes from
- Record sourced from PubMed, PMID 28692708.
- Also identified by DOI 10.1001/jamaneurol.2017.1336 and PMC identifier 5822186.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study examines the safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder.
Medical subject headings
- Antineoplastic Agents
- Aquaporin 4
- Bortezomib
- Neuromyelitis Optica